menu
    • menu

    Company profile for Olatec Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others. By selectively targeting N...
    Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others. By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL‑1β and IL‑18.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Olatec TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    New York, New York 10065
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.olatec.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/olatec/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/OlatecThera

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Marc Y. Joins Olatec’s Advisory Board As Immuno-Endocrinologist
    Marc Y. Joins Olatec’s Advisory Board As Immuno-Endocrinologist

    28 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250128658251/en

    BUSINESSWIRE
    28 Jan 2025
    Share Share
    First Patient Enrolled In Phase 2 Study Of Olatec's Dapansutrile For Diabetes
    First Patient Enrolled In Phase 2 Study Of Olatec's Dapansutrile For Diabetes

    11 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/first-patient-enrolled-in-a-phase-2-study-in-patients-with-type-2-diabetes-with-olatecs-nlrp3-inhibitor-dapansutrile-302194959.html

    PR NEWSWIRE
    11 Jul 2024
    Share Share
    Olatec to Conduct a Phase 2 Trial with its NLRP3 Inhibitor, Dapansutrile
    Olatec to Conduct a Phase 2 Trial with its NLRP3 Inhibitor, Dapansutrile

    20 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240220762945/en

    BUSINESSWIRE
    20 Feb 2024
    Share Share
    Olatec Announces Publication of Research on Oral NLRP3 Inhibitor Dapansutrile
    Olatec Announces Publication of Research on Oral NLRP3 Inhibitor Dapansutrile

    03 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231003370276/en

    BUSINESSWIRE
    03 Oct 2023
    Share Share
    Olatec Therapeutics Announces the Completion of First Dose Cohort
    Olatec Therapeutics Announces the Completion of First Dose Cohort

    16 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230516005286/en

    BUSINESSWIRE
    16 May 2023
    Share Share
    Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation
    Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation

    10 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230310005096/en

    BUSINESSWIRE
    10 Mar 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search